Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease.

Qian-Ya Fan Xiao-Dong Zhang Ze-Di Hu Shi-Shi Huang Shi-Guo Zhu Cai-Ping Chen Xiong Zhang Jian-Yong Wang

Front Neurol

Institute of Geriatric Neurology, Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.

Published: September 2022

Introduction: Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period.

Case Presentation: We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.

Conclusion: The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561359	PMC
http://dx.doi.org/10.3389/fneur.2022.961758	DOI Listing

Publication Analysis

Top Keywords

peak-dose dyskinesia

blepharospasm peak-dose

parkinson's disease

case report

blepharospasm

report blepharospasm

peak-dose

dyskinesia benefit

benefit amantadine

amantadine parkinson's

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!